GlassScriptPhysician profile
Catherine E Lasperches
NPI 1205857224
$2,635.80
in general payments reported to CMS, 2019-2025
22 companies · $806 in 2025
The $806 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $467 · 2023: $623 · 2024: $636 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $320.49 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Lilly USA, LLC | $285.69 | 2022-2024 | Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.00 | 2022-2023 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $162.32 | 2022-2025 | Uzedy |
| Bayer Healthcare Pharmaceuticals INC. | $139.67 | 2025 | |
| Abbvie INC. | $139.23 | 2024-2025 | |
| Janssen Biotech, INC. | $136.78 | 2025 | |
| Gilead Sciences, INC. | $131.73 | 2024 | Epclusa |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2023 | Opsumit, Uptravi |
| Alexion Pharmaceuticals, INC. | $124.95 | 2023 | |
| Neurelis, INC. | $123.56 | 2024 | Valtoco |
| Novo Nordisk INC | $123.46 | 2022 | |
| Madrigal Pharmaceuticals | $123.19 | 2025 | Rezdiffra |
| Genzyme Corporation | $109.67 | 2025 | |
| Neurocrine Biosciences, INC. | $104.04 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $98.49 | 2022 | |
| Boston Scientific Corporation | $75.29 | 2023 | |
| Exact Sciences Corporation | $38.58 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $19.66 | 2023 | Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $19.48 | 2024 | |
| Pfizer INC. | $17.67 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.86 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Lasperches listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.